Iressa Versus Docetaxel (Taxotere)
The purpose of this study is to compare the effects of ZD1839 or docetaxel in patients with advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based chemotherapy.
Non-Small-Cell Lung Carcinoma
DRUG: Gefitinib|DRUG: Docetaxel
To compare overall survival between ZD1839 and docetaxel
To compare time to progression (TTP) between ZD1839 and docetaxel|To compare progression-free rates at 4 months and 6 months between ZD1839 and docetaxel|To compare the overall objective tumor response rate between ZD1839 and docetaxel|To compare patient-reported functionality (PRF) and quality of life (QoL) between ZD1839 and docetaxel|To compare safety and tolerability of ZD1839 and docetaxel
The purpose of this study is to compare the effects of ZD1839 or docetaxel in patients with advanced non-small cell lung cancer (NSCLC) that has recurred or progressed after receiving prior treatment with platinum-based chemotherapy.